Fasiglifam (TAK-875): Mechanistic investigation and retrospective identification of hazards for drug induced liver injury

Toxicological Sciences

Volumn 163, Issue 2, 2018, Pages 374-384

  Otieno, Monicah A ^a   Snoeys, Jan ^b   Lam, Wing ^a   Ghosh, Avi ^a   Player, Mark R ^a   Pocai, Alessandro ^a   Salter, Rhys ^a   Simic, Damir ^a   Skaggs, Hollie ^a   Singh, Bhanu ^a   Lim, Heng Keang ^a  

^a API Large Molecule Pharmaceutical Development and Manufacturing Sciences   (United States)

^b Janssen Pharmaceutical Companies of Johnson and Johnson Discovery Support and Investigative Toxicology Preclinical Development and Safety   (Belgium)

Author keywords

Acyl glucuronide; DILI; Hepatic transporters; Metabolic activation; TAK 875

Indexed keywords

BILE SALT EXPORT PUMP; BILIRUBIN; FASIGLIFAM; GLUCURONIDE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; BENZOFURAN DERIVATIVE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN; ORGANIC ANION TRANSPORTER; PROTEIN BINDING; SULFONE; TAK-875;

ARTICLE; DOG; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG PROTEIN BINDING; HEP-G2 CELL LINE; HUMAN; IN VIVO STUDY; LIVER CELL; LIVER TOXICITY; MACACA FASCICULARIS; NONHUMAN; RAT; TOXICOKINETICS; TRANSPORT ASSAY; ANIMAL; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; DRUG EFFECT; GENE EXPRESSION; GENETICS; LIVER MITOCHONDRION; METABOLISM; OXYGEN CONSUMPTION; PATHOLOGY; PHYSIOLOGY; SPECIES DIFFERENCE; TOXIC HEPATITIS;

ANIMALS; BENZOFURANS; CHEMICAL AND DRUG INDUCED LIVER INJURY; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; HEP G2 CELLS; HEPATOCYTES; HUMANS; MACACA FASCICULARIS; MITOCHONDRIA, LIVER; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGANIC ANION TRANSPORTERS; OXYGEN CONSUMPTION; PROTEIN BINDING; RATS; SPECIES SPECIFICITY; SULFONES;

EID: 85042119986     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfx040     Document Type: Article

References (43)

1. Aleo, M. D., Luo, Y., Swiss, R., Bonin, P. D., Potter, D. M., and Will, Y. (2014). Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump. Hepatology 60, 1015-1022
2. Bloomer, J. C., Nash, M., Webb, A., Miller, B. E., Lazaar, A. L., Beaumont, C., and Guiney, W. J. (2013). Assessment of potential drug interactions by characterization of human drug metabolism pathways using non-invasive bile sampling. Br. J. Clin. Pharmacol. 75, 488-496
3. Boelsterli, U. A. (2003). Diclofenac-induced liver injury: A paradigm of idiosyncratic drug toxicity. Toxicol. Appl. Pharmacol. 192, 307-322
4. Boelsterli, U. A., and Lee, K. K. (2014). Mechanisms of isoniazidinduced idiosyncratic liver injury: Emerging role of mitochondrial stress. J. Gastroenterol. Hepatol. 29, 678-687
5. Darnell, M., and Weidolf, L. (2013). Metabolism of xenobiotic carboxylic acids: Focus on coenzyme A conjugation, reactivity, and interference with lipid metabolism. Chem. Res. Toxicol. 26, 1139-1155
6. Defossa, E., and Wagner, M. (2014). Recent developments in the discovery of FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitus. Bioorgan. Med. Chem. Lett. 24, 2991-3000
7. Fattinger, K., Funk, C., Pantze, M., Weber, C., Reichen, J., Stieger, B., and Meier, P. J. (2001). The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions. Clin. Pharmacol. Therap. 69, 223-231
8. Fontana, R. J. (2014). Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology 146, 914-928
9. Fontana, R. J., Hayashi, P. H., Gu, J., Reddy, K. R., Barnhart, H., Watkins, P. B., Serrano, J., Lee, W. M., Chalasani, N., Stolz, A., et al. (2014). Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology 147, 96-108 e4
10. Hofmann, A. F. (1999). The continuing importance of bile acids in liver and intestinal disease. Arch. Int. Med. 159, 2647-2658
11. Jungermann, K., and Katz, N. (1989). Functional specialization of different hepatocyte populations. Physiol. Rev. 69, 708-764
12. Kaku, K. (2013). Fasiglifam as a new potential treatment option for patients with type 2 diabetes. Expert Opin. Pharmacother. 14, 2591-2600
13. Kaku, K., Enya, K., Nakaya, R., Ohira, T., and Matsuno, R. (2015). Efficacy and safety of fasiglifam (TAK-875), a G proteincoupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: A randomized, double-blind, placebo-controlled, phase III trial. Diabetes Obes. Metab. 17, 675-681
14. Kaku, K., Enya, K., Nakaya, R., Ohira, T., and Matsuno, R. (2016). Long-term safety and efficacy of fasiglifam (TAK-875), a GPR40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: A 52-week open-label phase III study. Diabetes Obes. Metab. 18, 925-929
15. Kock, K., Ferslew, B. C., Netterberg, I., Yang, K., Urban, T. J., Swaan, P. W., Stewart, P. W., and Brouwer, K. L. (2014). Risk factors for development of cholestatic drug-induced liver injury: Inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4. Drug Metab. Dispos. 42, 665-674
16. Lassila, T., Hokkanen, J., Aatsinki, S. M., Mattila, S., Turpeinen, M., and Tolonen, A. (2015). Toxicity of carboxylic acid-containing drugs: The role of acyl migration and CoA conjugation investigated. Chem. Res. Toxicol. 28, 2292-2303
17. Leifke, E., Naik, H., Wu, J., Viswanathan, P., DeManno, D., Kipnes, M., and Vakilynejad, M. (2012). A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist TAK-875, in subjects with type 2 diabetes. Clin. Pharmacol. Therap. 92, 29-39
18. Leung, L., Kalgutkar, A. S., and Obach, R. S. (2012). Metabolic activation in drug-induced liver injury. Drug Metab. Rev. 44, 18-33
19. Mak, A., and Uetrecht, J. (2015a). The combination of anti-CTLA-4 and PD1-/-mice unmasks the potential of isoniazid and nevirapine to cause liver injury. Chem. Res. Toxicol. 28, 2289-2291
20. Mak, A., and Uetrecht, J. (2015b). The role of CD8 T cells in amodiaquine-induced liver injury in PD1-/-mice cotreated with anti-CTLA-4. Chem. Res. Toxicol. 28, 1567-1573
21. Marcinak, J., Smith, N., Oliveira, J., Smaoui, N., Friedman, M., Wolenski, F., Ohira, T., and Dragan, Y. (2016). Fasiglifam: Preclinical and Clinical Safety Considerations. Available at: https://www.aasld.org/sites/default/files/documents/DILI/2016/IV_6_Dragan_ppt.pdf. Accessed January 28, 2017
22. McMillian, M., Nie, A. Y., Parker, J. B., Leone, A., Bryant, S., Kemmerer, M., Herlich, J., Liu, Y., Yieh, L., Bittner, A., et al. (2004). A gene expression signature for oxidant stress/reactive metabolites in rat liver. Biochem. Pharmacol. 68, 2249-2261
23. Morgan, R. E., van Staden, C. J., Chen, Y., Kalyanaraman, N., Kalanzi, J., Dunn, R. T., 2nd, Afshari, C. A., and Hamadeh, H. K. (2013). A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol. Sci. 136, 216-241
24. Naik, H., Vakilynejad, M., Wu, J., Viswanathan, P., Dote, N., Higuchi, T., and Leifke, E. (2012). Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: Results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers. J. Clin. Pharmacol. 52, 1007-1016
25. Negoro, N., Sasaki, S., Mikami, S., Ito, M., Suzuki, M., Tsujihata, Y., Ito, R., Harada, A., Takeuchi, K., Suzuki, N., et al. (2010). Discovery of TAK-875: A potent, selective, and orally bioavailable GPR40 agonist. ACS Med. Chem. Lett. 1, 290-294
26. Pessayre, D., Fromenty, B., Berson, A., Robin, M. A., Letteron, P., Moreau, R., and Mansouri, A. (2012). Central role of mitochondria in drug-induced liver injury. Drug Metab. Rev. 44, 34-87
27. Rius, M., Nies, A. T., Hummel-Eisenbeiss, J., Jedlitschky, G., and Keppler, D. (2003). Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology 38, 374-384
28. Sawamura, R., Okudaira, N., Watanabe, K., Murai, T., Kobayashi, Y., Tachibana, M., Ohnuki, T., Masuda, K., Honma, H., Kurihara, A., et al. (2010). Predictability of idiosyncratic drug toxicity risk for carboxylic acid-containing drugs based on the chemical stability of acyl glucuronide. Drug Metab. Dispos. 38, 1857-1864
29. Schadt, S., Simon, S., Kustermann, S., Boess, F., McGinnis, C., Brink, A., Lieven, R., Fowler, S., Youdim, K., Ullah, M., et al. (2015). Minimizing DILI risk in drug discovery-A screening tool for drug candidates. Toxicol. In Vitro 30, 429-437
30. Schulz, S., Schmitt, S., Wimmer, R., Aichler, M., Eisenhofer, S., Lichtmannegger, J., Eberhagen, C., Artmann, R., Tookos, F., Walch, A., et al. (2013). Progressive stages of mitochondrial destruction caused by cell toxic bile salts. Biochim. Biophys. Acta 1828, 2121-2133
31. Shah, F., Leung, L., Barton, H. A., Will, Y., Rodrigues, A. D., Greene, N., and Aleo, M. D. (2015). Setting clinical exposure levels of concern for drug-induced liver injury (DILI) using mechanistic in vitro assays. Toxicol. Sci. 147, 500-514
32. Silva, M. F., Aires, C. C., Luis, P. B., Ruiter, J. P., IJlst L., Duran, M., Wanders, R. J., and Tavares de Almeida, I. (2008). Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: A review. J. Inherit. Metab. Dis. 31, 205-216
33. Sousa, T., Castro, R. E., Pinto, S. N., Coutinho, A., Lucas, S. D., Moreira, R., Rodrigues, C. M., Prieto, M., and Fernandes, F. (2015). Deoxycholic acid modulates cell death signaling through changes in mitochondrial membrane properties. J. Lipid Res. 56, 2158-2171
34. Takeda Press Release. 2015. Takeda Announces Termination of Fasiglifam (TAK-875) Development. Available at: http://www. takeda.us/newsroom/press_release_detail.aspx?year=2013&id=296. Accessed December 12, 2015
35. Thompson, R. A., Isin, E. M., Li, Y., Weidolf, L., Page, K., Wilson, I., Swallow, S., Middleton, B., Stahl, S., Foster, A. J., et al. (2012). In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs. Chem. Res. Toxicol. 25, 1616-1632
36. Tujios, S., and Fontana, R. J. (2011). Mechanisms of drug-induced liver injury: From bedside to bench. Nat. Rev. 8, 202-211
37. Uetrecht, J. (2008). Idiosyncratic drug reactions: Past, present, and future. Chem. Res. Toxicol. 21, 84-92
38. van der Schoor, L. W., Verkade, H. J., Kuipers, F., and Jonker, J. W. (2015). New insights in the biology of ABC transporters ABCC2 and ABCC3: Impact on drug disposition. Expert Opin. Drug Metab. Toxicol. 11, 273-293
39. Wagner, M., Zollner, G., and Trauner, M. (2009). New molecular insights into the mechanisms of cholestasis. J. Hepatol. 51, 565-580
40. Will, Y., Hynes, J., Ogurtsov, V. I., and Papkovsky, D. B. (2006). Analysis of mitochondrial function using phosphorescent oxygen-sensitive probes. Nat. Protoc. 1, 2563-2572
41. Woodhead, J. L., Yang, K., Siler, S. Q., Watkins, P. B., Brouwer, K. L., Barton, H. A., and Howell, B. A. (2014). Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury. Front. Pharmacol. 5, 240
42. Yang, K., Woodhead, J. L., Watkins, P. B., Howell, B. A., and Brouwer, K. L. (2014). Systems pharmacology modeling predicts delayed presentation and species differences in bile acid-mediated troglitazone hepatotoxicity. Clin. Pharmacol. Therap. 96, 589-598
43. Zelcer, N., Saeki, T., Bot, I., Kuil, A., and Borst, P. (2003). Transport of bile acids in multidrug-resistance-protein 3-overexpressing cells co-transfected with the ileal Na+-dependent bileacid transporter. Biochem. J. 369, 23-30